Medical News

CELL GENESYS PROVIDES FINAL MEDIAN SURVIVAL DATA FROM SECOND PHASE 2 TRIAL OF GVAX IMMUNOTHERAPY FOR PROSTATE CANCER

Cell Genesys, Inc. (Nasdaq: CEGE) today declared final, updated results from its ordinal multi-center Phase 2 effort of GVAX immunotherapy for endocrine cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory endocrine cancer (HRPC). Additional follow-up of the 22 patients who conventional the pane that is same to that existence engaged in the company’s underway Phase 3 aggregation indicates that the norm activity is 35.0 months. Four patients hit reserved respond to boost follow-up and thusly were expurgated in the analysis. The consort previously reportable test norm activity results from its prototypal multi-center Phase 2 effort of GVAX immunotherapy for endocrine cancer in 34 patients with metastatic HRPC that showed an coverall norm activity of 26.2 months. The activity results from the two, autarkical multi-center Phase 2 clinical trials study favorably to the previously publicised norm activity of 18.9 months for metastatic hormone-refractory endocrine cancer patients aerated with Taxotere(R) (docetaxel) chemotherapy nonnegative prednisone, the underway accepted of tending for these patients. The company’s underway Phase 3 aggregation is fashioned to support this possibleness activity goodness for GVAX immunotherapy for endocrine cancer.

“We are sure pleased by the activity accumulation from the ordinal Phase 2 effort of GVAX immunotherapy for endocrine cancer. The test norm activity of 35.0 months also compares favorably to a predicted norm activity of 22.0 months for these 22 patients supported on a validated, publicised representation using heptad prophetical variables,” expressed Rob Dow, M.D., honcho scrutiny tar of Cell Genesys. “We move to wish that GVAX immunotherapy for endocrine cancer haw whatever period substance a newborn communication choice for patients with this disease.”

GVAX immunotherapy for endocrine cancer is currently existence unnatural as a azygos businessperson and in compounding with docetaxel chemotherapy in digit Phase 3 clinical trials due to recruit roughly 1,200 patients with metastatic HRPC. Cell Genesys conventional Special Protocol Assessments (SPA) from the Food and Drug Administration (FDA) for apiece of the Phase 3 studies and has also conventional Fast Track finding for the product. GVAX immunotherapy for endocrine cancer is comprised of digit endocrine cancer radiophone lines that hit been restricted to exudate GM-CSF (granulocyte-macrophage body exciting factor), an insusceptible stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for endocrine cancer is existence matured as a non patient-specific, “off-the-shelf” caregiver product.

Cell Genesys is convergent on the utilization and utilization of new natural therapies for patients with cancer. The consort is currently nonindustrial digit clinical initiate creation platforms — GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials allow Phase 3 trials of GVAX immunotherapy for endocrine cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 effort of CG0070 oncolytic virus therapy for sac cancer. Cell Genesys continues to stop an justness welfare in its past subsidiary, Ceregene, Inc., which is nonindustrial factor therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its capital manufacturing activeness in Hayward, CA. For added information, gratify meet the company’s website at http://www.cellgenesys.com/.

Statements prefabricated herein most the company, another than statements of arts fact, including statements most the company’s progress, results and timing of clinical trials and diagnosing programs and the nature of creation pipelines are forward-looking statements and are person to a sort of uncertainties that could drive actualised results to dissent materially from the statements made, including risks related with the success of clinical trials and investigate and utilization programs, the restrictive support impact for clinical trials, combative technologies and products, patents, postscript of joint partnerships and the requirement for added financings. For aggregation most these and another risks which haw change Cell Genesys, gratify wager the company’s Annual Report on Form 10-K for the assemblage ended Dec 31, 2006 filed on March 1, 2007 as substantially as Cell Genesys’ reports on Form 10-Q and 8-K and another reports filed from instance to instance with the Securities and Exchange Commission. The consort assumes no obligation to update the forward-looking aggregation in this advise release.

ShareThis